Co-founder, Silicon Therapeutics; Associate Professor of Surgery, Harvard Medical School, Beth Israel Deaconess Medical Center
Lijun Sun, Ph.D. is a co-founder of Silicon Therapeutics. Dr. Sun started his professional career in drug discovery and development in 1997, and oversaw drug discovery at Shionogi BioResearch Corp as director of chemistry (2000-2002), as senior director and vice president of chemistry at Synta Pharmaceuticals, Inc. and as vice president of chemistry and pharmaceutical sciences at Theracrine, Inc.
Dr. Sun has more than 140 awarded and pending U.S. patents, and as a senior executive at three biotechnology companies, he discovered a number of novel small molecules drug candidates, including PIKfyve inhibitor apilimod (phase-2 in inflammatory bowel disease), ROS inducer elesclomol (Phase-3 in metastatic melanoma, co-development with GSK) and CRAC channel blocker Ro-2959 (pre-clinical in arthritis, co-development with Roche).
Dr. Sun earned a doctor of philosophy organic chemistry from Emory University in Atlanta 1995 and completed postdoctoral training in biomaterial research at Emory School of Medicine in Atlanta in 1997.